Additionally, interleukin 16 protein levels have been reported to be altered in a molecular profiling study on serum samples of MDD patients (Stelzhammer et al., 2014) and to be associated with symptom severity in schizophrenia (Schwarz et al., 2012). The gene discussed is IL16; the disease is schizophrenia.